Status:
COMPLETED
Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan
Lead Sponsor:
AbbVie
Conditions:
Psoriasis
Eligibility:
All Genders
20+ years
Brief Summary
Psoriasis (PsO) is a chronic, disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques and is associated with high burden of illness that results in a negativ...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of moderate to severe chronic plaque-type psoriasis diagnosed by a specialist t at the time of recruitment.
- Initiating an approved biologic treatment for psoriasis as per regulatory and reimbursement policy in Taiwan. Physician's decision with any of the above-mentioned treatments must have been reached prior to and independently of recruitment in the study.
- Treatments prescribed in accordance to both the product monograph, regulatory and reimbursement policies in Taiwan.
Exclusion
- \- Participation in an interventional clinical trial, concurrently or within the last 30 days. Participation in another PMOS or Registry is acceptable.
Key Trial Info
Start Date :
May 31 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2025
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT04818385
Start Date
May 31 2021
End Date
August 1 2025
Last Update
September 17 2025
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital /ID# 230017
Taipei City, Taipei, Taiwan, 100
2
National Taiwan University Hospital - Hsinchu branch /ID# 238432
Hsinchu, Taiwan, 30059
3
Hualien Tzu Chi Hospital /ID# 238431
Hualien City, Taiwan, 97002
4
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 230016
Kaohsiung City, Taiwan, 807